title: Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea.
abstract: BACKGROUND
  B-type natriuretic peptide (BNP) is a quantitative marker of heart failure that seems to be helpful in its diagnosis.
  
  
  METHODS
  We performed a prospective randomized study (B-Type Natriuretic Peptide for Acute Shortness of Breath Evaluation) including 452 patients who presented to the emergency department with acute dyspnea to estimate the long-term cost-effectiveness of BNP guidance. Participants were randomly assigned to a diagnostic strategy involving the measurement of BNP levels (n = 225) or assessment in a standard manner (n = 227). Nonparametric bootstrapping was used to estimate the distribution of incremental costs and effects on the cost-effectiveness plane during 180 days of follow-up.
  
  
  RESULTS
  Testing of BNP induced several important changes in management of dyspnea, including a reduction in the initial hospital admission rate, the use of intensive care, and total days in the hospital at 180 days (median, 10 days [interquartile range, 2-24 days] in the BNP group vs 14 days [interquartile range, 6-27 days] in the control group; P = .005). At 180 days, all-cause mortality was 20% in the BNP group and 23% in the control group (P = .42). Total treatment cost was significantly reduced in the BNP group (7930 dollars vs 10,503 dollars in the control group; P = .004). Analysis of incremental 180-day cost-effectiveness showed that BNP guidance resulted in lower mortality and lower cost in 80.6%, in higher mortality and lower cost in 19.3%, and in higher or lower mortality and higher cost in less than 0.1% each. Results were robust to changes in most variables but sensitive to changes in rehospitalization with BNP guidance.
  
  
  CONCLUSIONS
  Testing of BNP is cost-effective in patients with acute dyspnea.
authors.affiliation: Department of Internal Medicine, University Hospital, University of Basel, Basel, Switzerland. chmueller@uhbs.ch
authors.forename: Christian
authors.initials: C
authors.lastname: Mueller
authors.forename: Kirsten
authors.initials: K
authors.lastname: Laule-Kilian
authors.forename: Christian
authors.initials: C
authors.lastname: Schindler
authors.forename: Theresia
authors.initials: T
authors.lastname: Klima
authors.forename: Barbara
authors.initials: B
authors.lastname: Frana
authors.forename: Daniel
authors.initials: D
authors.lastname: Rodriguez
authors.forename: André
authors.initials: A
authors.lastname: Scholer
authors.forename: Michael
authors.initials: M
authors.lastname: Christ
authors.forename: André P
authors.initials: AP
authors.lastname: Perruchoud
mesh_terms: D000208:Acute Disease; D000368:Aged; D003362:Cost-Benefit Analysis; D003937:Diagnosis, Differential; D004417:Dyspnea / Q000097:blood / Q000175:diagnosis / Q000191:economics*; D005260:Female; D015200:Fluoroimmunoassay / Q000191:economics; D006801:Humans; D007902:Length of Stay / Q000191:economics; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood / Q000191:economics*; D011446:Prospective Studies; D016037:Single-Blind Method
chemical_list: D020097:Natriuretic Peptide, Brain